Madrigal Pharmaceuticals (MDGL) to Release Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is projected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($4.2296) per share and revenue of $301.0650 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing the consensus estimate of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The business had revenue of $321.08 million for the quarter, compared to analysts’ expectations of $310.36 million. During the same quarter in the prior year, the company posted ($2.71) EPS. The business’s revenue for the quarter was up 210.8% on a year-over-year basis. On average, analysts expect Madrigal Pharmaceuticals to post $-5 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL opened at $518.66 on Tuesday. Madrigal Pharmaceuticals has a 12 month low of $265.00 and a 12 month high of $615.00. The stock has a fifty day moving average price of $483.13 and a 200-day moving average price of $505.30. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. The firm has a market cap of $11.95 billion, a PE ratio of -40.30 and a beta of -1.04.

Analysts Set New Price Targets

MDGL has been the subject of several analyst reports. Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a report on Tuesday, January 6th. TD Cowen reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, April 21st. The Goldman Sachs Group reiterated a “buy” rating and set a $571.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. Finally, Zacks Research upgraded Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $685.31.

Insider Buying and Selling

In related news, insider Carole Huntsman sold 419 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total value of $180,982.86. Following the completion of the transaction, the insider owned 12,692 shares in the company, valued at $5,482,182.48. This trade represents a 3.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO William John Sibold sold 1,663 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total value of $718,316.22. Following the completion of the transaction, the chief executive officer owned 161,829 shares of the company’s stock, valued at $69,900,418.26. This trade represents a 1.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,098 shares of company stock worth $2,626,254 over the last three months. Corporate insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Abel Hall LLC purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter worth $271,000. PharVision Advisers LLC purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter worth $267,000. Quantitative Investment Management LLC purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter worth $260,000. Integrated Investment Consultants LLC purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter worth $260,000. Finally, Amundi purchased a new position in Madrigal Pharmaceuticals in the 4th quarter worth $254,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.